Generic Duzallo Availability
Last updated on May 7, 2025.
Duzallo is a brand name of allopurinol/lesinurad, approved by the FDA in the following formulation(s):
DUZALLO (allopurinol; lesinurad - tablet;oral)
-
Manufacturer: IRONWOOD PHARMS INC
Approval date: August 18, 2017
Strength(s): 200MG;200MG (discontinued) [RLD], 300MG;200MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duzallo. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compounds and compositions and methods of use
Patent 10,183,012
Issued: January 22, 2019
Inventor(s): Quart Barry D. & Girardet Jean-Luc & Gunic Esmir & Yeh Li-Tain
Assignee(s): Ardea Biosciences, Inc.Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Patent expiration dates:
- November 26, 2028✓
- November 26, 2028
-
2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acet- ic acid and methyl ester
Patent 8,003,681
Issued: August 23, 2011
Inventor(s): Girardet; Jean-Luc et al.
Assignee(s): Ardea Biosciences, Inc. (San Diego, CA)A series of S-triazolyl .alpha.-mercaptoacetanilides having general structure (1) are provided, where Q is CO.sub.2H, CONR.sub.2, SO.sub.3H, or SO.sub.2NR.sub.2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections. ##STR00001##
Patent expiration dates:
- August 25, 2025✓
- August 25, 2025
-
Compounds and compositions and methods of use
Patent 8,084,483
Issued: December 27, 2011
Inventor(s): Quart; Barry D. et al.
Assignee(s): Ardea Biosciences, Inc. (San Diego, CA)Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Patent expiration dates:
- August 17, 2029✓
- August 17, 2029
-
Compounds and compositions and methods of use
Patent 8,283,369
Issued: October 9, 2012
Inventor(s): Quart Barry D. & Girardet Jean-Luc & Gunic Esmir & Yeh Li-Tain
Assignee(s): Ardea Biosciences. Inc.Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Patent expiration dates:
- November 26, 2028✓
- November 26, 2028
-
Compounds and compositions and methods of use
Patent 8,357,713
Issued: January 22, 2013
Inventor(s): Quart Barry D. & Girardet Jean-Luc & Gunic Esmir & Yeh Li-Tain
Assignee(s): Ardea Biosciences Inc.Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Patent expiration dates:
- December 22, 2029✓✓
- December 22, 2029
-
H
Patent 8,546,436
Issued: October 1, 2013
Inventor(s): Treiber Laszlo R. & Galvin Gabriel & Zamansky Irina & Girardet Jean-Luc
Assignee(s): Ardea Biosciences, Inc.Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
Patent expiration dates:
- February 29, 2032✓
- February 29, 2032
-
Compounds and compositions and methods of use
Patent 8,546,437
Issued: October 1, 2013
Inventor(s): Quart Barry D. & Girardet Jean-Luc & Gunic Esmir & Yeh Li-Tain
Assignee(s): Ardea Biosciences, Inc.Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
Patent expiration dates:
- April 29, 2029✓
- April 29, 2029
-
Treatment of gout and hyperuricemia
Patent 9,216,179
Issued: December 22, 2015
Inventor(s): Miner Jeffrey & Girardet Jean-Luc & Quart Barry D.
Assignee(s): ARDEA BIOSCIENCES, INC.Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
Patent expiration dates:
- August 1, 2031✓
- August 1, 2031
-
Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Patent 9,956,205
Issued: May 1, 2018
Inventor(s): Treiber Laszlo R. & Zamansky Irina & Girardet Jean-Luc
Assignee(s): Ardea Biosciences, Inc.Crystalline polymorph forms of 2-(5-bromo-4-(4-cyclopropyl naphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid are described. Pharmaceutical compositions and the uses of such compounds, compound forms, and compositions for the treatment of a variety of diseases and conditions are also presented.
Patent expiration dates:
- December 28, 2031✓
- December 28, 2031
More about Duzallo (allopurinol / lesinurad)
- Duzallo consumer information
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antihyperuricemic agents
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
